UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) June 17, 2005
-------------
Nephros, Inc.
-------------
(Exact Name of Registrant as Specified in Charter)
Commission File Number: 001-32288
---------
Delaware 13-3971809
-------- ----------
(State or other Jurisdiction of (I.R.S. Employer
Incorporation) Identification No.)
3960 Broadway, New York, New York 10032
---------------------------------------
(Address of Principal Executive Offices)
(Zip Code)
(212) 781-5113
--------------
(Registrant's telephone number, including area code)
Not Applicable
--------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 17, 2005, Nephros, Inc. issued a press release announcing the
510(k) approval of its OLpur(TM) HD190 dialyzer from the United States Food and
Drug Administration. The full text of this press release is attached hereto as
Exhibit 99.1. The information in this report shall not be deemed to be "filed"
for the purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liability of that Section.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release issued by Nephros, Inc. dated June 17, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 17, 2005
NEPHROS, INC.
By: /s/ Marc L. Panoff
---------------------------------
Marc L. Panoff
Chief Financial Officer (Principal
Financial and Accounting Officer)